Newsroom press releases

19/09/25 - 9:34

Diasorin launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark (130.17 KB)

Products Immunodiagnostic

08/09/25 - 11:16

New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025 (136.64 KB)

Products Immunodiagnostic

31/07/25 - 16:22

Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed (238.17 KB)

Financial Data

02/07/25 - 8:10

Diasorin submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver (133.82 KB)

Products Molecular

07/06/25 - 12:25

Diasorin announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (143.05 KB)

Products Molecular

06/05/25 - 17:41

Revenue growing +8% and EBITDA margin at 34%: Q1 Results confirm FY 2025 Guidance (268.56 KB)

Financial Data

18/04/25 - 18:11

Diasorin receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX® (161.29 KB)

Products

18/03/25 - 11:54

Diasorin launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark (126.65 KB)

Products Molecular

14/03/25 - 16:29

The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share (239.79 KB)

Financial Data